Hôpital Pellegrin

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Source

• Recruiting

  A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

  NCT07444450· Phase 3· Source

• Not yet recruiting

  Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

  2026-525463-40-00· Phase 1/2· Source

• Not yet recruiting

  Efficacy of FLUOXETINE in children with drug-resistant, complex and rare epilepsy (FLUOXEPIL)

  2024-519897-38-01· Phase 3· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Source

• Not yet recruiting

  CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

  NCT07402044· Source

• Recruiting

  Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS

  NCT07091799· Source

• Not yet recruiting

  Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.

  NCT07379957· Source

• Recruiting

  A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

  NCT07266831· Phase 2/3· Source

• Active, not recruiting

  A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis

  2024-519291-11-00· Phase 2· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· Phase 3· Source

• Recruiting

  ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir based antiretroviral regimens in treatment-naïve people living with HIV-1 infection

  NCT06203132· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  NCT06617325· Phase 3· Source

• Active, not recruiting

  Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

  NCT06321601· Phase 3· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  NCT06461897· Phase 3· Source

• Recruiting

  HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

  NCT05373264· Phase 3· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

  NCT06100744· Phase 3· Source

• Active, not recruiting

  A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· Phase 3· Source

• Recruiting

  Intensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy

  NCT05609084· Source

• Recruiting

  Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

  NCT05433441· Source

• Recruiting

  A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

  NCT05533775· Phase 1/2· Source

• Recruiting

  Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

  NCT04925609· Phase 1/2· Source

• Recruiting

  Hizentra® in Inflammatory Neuropathies - pHeNIx Study

  NCT04672733· Source

• Recruiting

  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

  NCT05065216· Phase 2/3· Source

• Enrolling by invitation

  A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

  NCT04976322· Phase 3· Source

• Active, not recruiting

  Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD

  NCT04676854· Source

• Recruiting

  A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  NCT04094610· Phase 1/2· Source

• Active, not recruiting

  Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

  NCT04044768· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Source

• Recruiting

  French Registry for Monitoring Pregnancies for Multiple Sclerosis

  NCT03900221· Source

• Active, not recruiting

  Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2) - NIVO ALCL

  2024-516807-17-00· Phase 2· Source

• Active, not recruiting

  Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients

  NCT03643133· Phase 2· Source

• Active, not recruiting

  Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

  NCT03407144· Phase 2· Source

• Active, not recruiting

  Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV

  NCT03296202· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

  NCT03100149· Phase 2· Source

• Recruiting

  European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

  NCT02813135· Phase 1/2· Source

• Active, not recruiting

  Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

  NCT00470223· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers6 recruiting
• HIV3 recruiting
• Amyloidosis2 recruiting
• Epilepsy2 recruiting
• Lupus (SLE)2 recruiting
• Parkinson disease2 recruiting
• ALS (motor neurone disease)1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Multiple sclerosis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Polycystic kidney disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoma1 recruiting
• Spinal muscular atrophy1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· Source

• Completed

  Characterization of Immune Response in Participants from a Posdinemab Study

  2024-514634-20-00· Phase 1· Source

• Completed

  Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA

  2024-516028-33-01· Phase 3· Source

• Completed

  Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial

  NCT04667078· Phase 4· Source

• Completed

  A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.

  2022-500275-31-00· Phase 3· Source

• Terminated

  Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.

  NCT05492604· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Completed

  An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s disease

  NCT05543252· Phase 2· Source

• Completed

  Aging With HIV and Neurocognitive Decline, a Follow-up Study

  NCT05385588· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

  NCT05248646· Phase 3· Source

• Completed

  Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

  NCT04788615· Phase 3· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease

  2022-501188-42-00· Phase 2· Source

• Completed

  A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

  NCT04374136· Phase 3· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Source

• Completed

  Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

  NCT03891446· Phase 3· Source

• Completed

  Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.

  NCT03464344· Source

• Completed

  A Study Evaluating the Safety and Efficacy of KTE-X19 in pediatric and adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory Non-Hodgkin Lymphoma.

  2023-509440-97-00· Phase 1· Source

• Active, not recruiting

  A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

  NCT01946204· Phase 3· Source

Trial sites

• Hopital Pellegrin8 trials
• Hopital Pellegrin - Site #4310 trials
• Hopital Pellegrin _ Soins Intensifs Unite Neurovasculaire0 trials
• Pellegrin Hospital48 trials
• service de maladies infectieuses et médecine tropicale - Hôpital Pellegrin1 trial
• Service EFSN - Hôpital Pellegrin1 trial